Cysteine-Mutant Antibody TLR Agonist Immunoconjugates for Inaccessible Tumors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current compositions and methods for delivering antibodies and immune adjuvants are inadequate for accessing inaccessible tumors, limiting treatment options for cancer patients.

Innovation Solution

Development of an immunoconjugate comprising a cysteine-mutant antibody covalently attached to one or more TLR agonist moieties via a linker, enabling targeted delivery and enhanced immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional antibody delivery methods are used, then the treatment is simple to administer, but the antibodies cannot access inaccessible tumors

Engineering Contradiction:

Improveaccess to inaccessible tumorsVSAvoiddelivery system complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent combines antibodies with TLR agonist adjuvants into a single immunoconjugate molecule, enabling the delivery system to simultaneously provide targeted tumor binding and immune stimulation capabilities that conventional separate administrations cannot achieve

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The immunoconjugate uses composite structure combining antibody components with TLR agonist moieties linked through chemical linkers, creating a material with enhanced functionality that can access and treat previously inaccessible tumors

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional antibody delivery is used, then the administration process is simple, but the immune response against tumors is insufficient

Engineering Contradiction:

Improveimmune response effectivenessVSAvoidconjugate structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges antibody targeting functionality with TLR agonist immune-stimulating functionality into one molecule, ensuring reliable immune activation against tumors while maintaining targeted delivery

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The TLR agonist moiety acts as an intermediary that bridges the gap between antibody binding and effective immune response, translating target recognition into potent immune activation through TLR signaling pathways

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If multiple separate treatments are administered, then each treatment can be optimized, but the treatment protocol becomes complex

Engineering Contradiction:

Improvetreatment optimizationVSAvoidadministration simplicity

Core Design Contradiction:

Adaptability or versatilityVSEase of operation

Solution Approach 1:

The immunoconjugate combines multiple therapeutic functions (targeted binding and immune adjuvancement) into a single administrable unit, simplifying the treatment protocol while maintaining the benefits of optimized components

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The immunoconjugate structure is designed to perform multiple functions simultaneously - targeted tumor binding via antibody and immune system activation via TLR agonist - eliminating the need for separate administered treatments

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The immunoconjugate effectively activates immune cells to secrete IL-12p70, promoting an immune response against tumor cells, thereby expanding treatment options for cancer and other conditions.

Implementation Method 1

an immunoconjugate comprising a cysteine-mutant antibody covalently attached to one or more TLR agonist moieties by a linker

Methodology Applied

Scientific EffectCovalent bonding: Chemical Bonding

Implementation Method 2

The immunoconjugate effectively activates immune cells to secrete IL-12p70, promoting an immune response against tumor cells

Methodology Applied

Scientific EffectImmune cell activation:

Data Source

PatentUS20250000995A1TLR agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof

Publication Date: 2025.01.02 BOLT BIOTHERAPEUTICS INC

AI summary

The invention provides immunoconjugates comprising a cysteine-mutant antibody covalently attached to one or more TLR agonist moieties by a linker. The invention further provides methods of treating cancer with the immunoconjugates.